Disclosure Insight Maintains High Risk Rating on Medivation

A report from Disclosure Insight reiterates its High Risk rating on Medivation MDVN. The report states, “Concentrated revenue with two partners, one of which has the ability to terminate the relationship due to poor clinical data, supports our opinion of a High Risk rating on MDVN. On 3-Mar-10, the company disclosed that its lead product candidate, dimebon, did not meet its co-primary or secondary goals in the Phase 3 CONNECTION study. The negative results gave Pfizer the right to terminate its collaboration agreement with MDVN at any time." MDVN closed yesterday at $16.69.